Approved Risk Evaluation and Mitigation Strategies (REMS)

Contact Us | REMS Basics | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Androgel 1% (testosterone)
NDA #021015
REMS last update: 05/11/2015



What is the purpose of the REMS?

To inform patients about the serious risks associated with the use of AndroGel (testosterone gel) 1%.

What do participants need to know?

Healthcare providers should read the relevant Medication Guide or communication materials included in the product-specific approved REMS to learn about the risk(s).

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Androgel 1% REMS, see the DailyMed link(s).
Material Name Material Name Link
REMS document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Androgel_1_2015.05.11_REMS_document.pdf

What updates have been made to the REMS?

Date Summary of change
05/11/2015 Modified to add the risk of major adverse cardiovascular events associated with testosterone replacement therapy to the Medication Guide.
11/12/2014 Modified to add a new application site diagram in the Medication Guide.
06/19/2014 Modified to add the risk of venous thromboembolic events associated with testosterone use to the Medication Guide.
05/20/2013 Modified to add the new applicant name, address, and contact information to the Medication Guide.
09/20/2012 Modified to add information that is consistent with labeling provided for AndroGel® (testosterone gel) 1.62% in the Medication Guide.
11/30/2011 Modified to add information about the risk of secondary exposure in children in the Medicaiton Guide.
03/10/2011 Modified to

  1. make revisions to the Medication Guide including the updates to the Medication Guide text described above [in the approval letter]
  2. replace Solvay Pharmaceuticals, Inc with the name and address of Abbott Products, Inc.
09/18/2009 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English